To clarify species differences in the developmental toxicity of procymidone (Sumilex ® , a fungicide for agricultural use), placental transfer studies were conducted using 14 C-labeled procymidone in pregnant rats, rabbits, and monkeys. These studies demonstrated that maternal-to-fetal transfer of the parent compound and its hydroxylated metabolite, which are both weak anti-androgenic agents, occurred more easily than that of other metabolites, with much higher absolute concentrations achieved in the fetal circulation of rats than of rabbits or monkeys. Notably, in rats, the fetal plasma concentration of the hydroxylated metabolite was higher than that of procymidone, especially after repeated oral administration of procymidone. These results suggest that the hydroxylated metabolite is the most relevant metabolite involved in teratogenic activity in rats.
Introduction
Procymidone (Sumilex ® ) is a fungicide with both protective and curative properties. It is used to control plant diseases such as fruit rots, gray mold on fruits, vines, and vegetables; and Sclerotinia rot of kidney beans and vegetable crops. [1] [2] [3] Regarding the developmental toxicity of this fungicide, toxicity studies have demonstrated the development of abnormalities in the external genitalia of male rats. However, developmental toxicity studies failed to detect such abnormalities in rabbits or monkeys. [4] [5] [6] Previous in vivo metabolism studies of procymidone in rats and mice have extensively investigated the metabolic fate of procymidone. [7] [8] [9] The major biotransformation reactions are known to be the oxidation of the hydroxymethyl group to alcohol and carboxylic acid, and the glucuronidation of derived hydroxylated metabolites (Fig. 1) . On the other hand, the cleavage of the imide linkage is observed for procymidone and its metabolites, and both compounds (with an imide ring and its cleaved moiety) are interchangeably converted back and forth in equilibrium, depending on the pH of the plasma or tissues. 10) In this article, the following abbreviations are used for procymidone and its metabolites: PCM (sum of procymidone and PCM-NH-COOH), Hydroxylated-PCM (sum of PCM-CH 2 OH and PA-CH 2 OH), Carboxylated-PCM (sum of PCM-COOH and PA-COOH), and Hydroxylated-PCM-glucuronide (sum of PCM-CH 2 OH-glucuronide and PA-CH 2 OH-glucuronide).
To clarify the reason for species differences in developmental toxicity, a series of mechanism studies have been conducted. In vitro receptor binding assays demonstrated that only PCM and Hydroxylated-PCM have weak anti-androgenic activity. 11, 12) Previous in vivo experiments using intact animals showed that Hydroxylated-PCM could be a key factor in determining teratogenicity in rats but not rabbits or monkeys. 6) After being administered, chemicals are distributed throughout the bodies of animals and metabolized. Generally, the concentrations of chemicals including their metabolites are higher in maternal plasma and placenta than in the fetus and amniotic fluid. This means that chemicals are not readily transferred from maternal plasma to the fetus due to transporters found in the placental barrier systems of all species. 13, 14) Some chemicals administered to pregnant animals can cross the placenta and reach the fetus. The variability of chemical transfer to the fetus via the placenta is considered to depend on the properties of the administered chemicals and on maternal conditions. The following parameters were considered possible fac-tors determining the extent of placental transfer: (i) the molecular weight of the chemical; (ii) its pK a (pH at which the chemical is 50% ionized); (iii) the extent of chemical binding to the plasma protein, and (iv) its affinity to the transporters in placentas. For example, ampicillin and methicillin are both completely transferred and both strongly dissociated at physiological pH. 15) Therefore, the present placental transfer studies were conducted to confirm (1) whether the results of previous experiments in intact animals will be reproduced in pregnant animals, (2) how the active substances are transferred to the fetus, and (3) whether the behaviors of these substances differ in fetal rats, rabbits, and monkeys.
This study measured the concentrations of 14 C and metabolites in the amniotic fluid, fetuses, maternal plasma, and placentas of pregnant rats, rabbits, and monkeys after the oral administration of procymidone.
Materials and Methods

Test substances and vehicle [phenyl-
14 C] Procymidone (specific activity 4.48 GBq/mmol [15.6 MBq/mg], radiochemical purity 98.0%) purchased from Amersham Bioscience UK Limited, and procymidone (chemical purity 99.1%) synthesized at our company were used as the labeled and unlabeled test substances, respectively. Corn oil (Wako Pure Chemical Industries, Ltd., Japan) for rats and a 0.5 w/v% methylcellulose (MC; Wako) solution for rabbits and monkeys were used as vehicles. Five authentic metabolite standards synthesized at our laboratory were used for the identification of metabolites: PCM-CH 2 OH (chemical purity 99.9%), PCM-COOH (chemical purity 94.7%), PCM-NH-COOH (chemical purity 98.6%), PA-CH 2 OH (chemical purity 98.8%), and PA-COOH (chemical purity 96.9%).
Thin layer chromatography (TLC)
Coated silica gel 60F 254 TLC plates (20×20 cm, 0.25 mm thickness, Merck, Germany) were employed for the chemical analysis of metabolites and to confirm the stability of procymidone in dosing formulations with the following solvent systems: (1) toluene/ethyl formate/formic acid (5 : 7 : 1, by vol.), (2) n-butanol/ acetic acid/water (6 : 1 : 1, by vol.), and (3) hexane/diethyl ether (1 : 2, by vol.). Metabolites were identified by TLC co-chromatography with authentic standards. Unlabeled chemicals were visualized under ultraviolet light. Radioactive chemicals on developed TLC plates were detected using an imaging analyzer (BAS-1800 II and FLA, Fuji Photo Film Co., Ltd., Japan) with imaging plates (Fuji Photo Film). Solvent systems (1) and (2) were used to analyze the metabolites in plasma and tissues. Solvent system (3) was used to confirm the stability of procymidone in dosing formulations.
Radioanalysis
Radioactivity in liquid samples was measured with a liquid scintillation counter (Tri-Carb 2500TR and 2700TR; PerkinElmer Inc., USA). Radioactivity in the dosing formulations, plasma, amniotic fluid, and extracts of plasma and tissues (maternal plasma, liver, kidney, placenta, and fetus) was measured directly with a liquid scintillator (Ultima Gold; PerkinElmer Inc.). Tissue homogenates and non-extractable residues were combusted using a sample oxidizer (System 307; PerkinElmer Inc.) with a carbon dioxide absorbing agent (Carbo-Sorb and Permafluor; PerkinElmer Inc.), and radioactivity was then measured in the absorbing agent.
Preparation of dosing formulations
The dose of [phenyl- 14 C] procymidone was set at 125 mg/7.40 MBq/kg for rats and rabbits, and 125 mg/15 MBq/ kg for monkeys. The volume of the corn oil vehicle was set at 5 mL/kg for rats and 0.5 w/v% MC solution vehicle for rabbits and monkeys. The 14 C-labeled test substance was diluted with an unlabeled test substance in acetone to adjust the appropriate specific radioactivity. The solution was evaporated to dryness, mixed using a mortar and pestle, and then dissolved in corn oil or dispersed in a 0.5 w/v% MC solution to make a homogeneous dosing formulation. An aliquot of the dosing formulation was diluted with acetone to check the purity and concentration of the procymidone. In an earlier study, it was demonstrated that these different vehicles had no effect on pharmacokinetics or excretion.
Treatment of pregnant animals
The study protocol was approved by the animal protection committee at each laboratory, and the study was performed in accordance with their established ethical standards. The timing of the administration was set based on the critical period of differentiation of the external genitalia in each animal (single administration: rat, the 17th day of pregnancy: rabbit, the 21st day of pregnancy: monkey, the 54th day of pregnancy; repeated administration: rat, the 16th to 18th day of pregnancy).
5.1. Single oral dose in rats Crj:CD (SD strain) IGS female rats were used on the 17th day of pregnancy (12 weeks of age). Eleven-week-old rats on the 9th day of pregnancy were purchased from Charles River Japan, Inc. The first day that a vaginal plug was observed was taken as gestation day zero (GD0). The health status of the rats was checked during a quarantine and acclimation period of one week. Pregnant rats had access to food (CRF-1; Oriental Yeast, Co., Ltd., Japan) and water ad libitum during the experiment. [phenyl-14 C] Procymidone was administered to 2 groups of 3 pregnant rats each by oral gavage at 125 mg/kg. One group was sacrificed 6 hr after administration, and the other group was sacrificed at 24 hr.
Single oral dose in rabbits
Twenty-three-week-old Kbs:NZW female rabbits were purchased on the 14th day of pregnancy from Kitayama Laboratories Co. (Japan) and used one week later on the 21st day of pregnancy. The health status of the rabbits was checked during the 1-week quarantine and acclimation period. Pregnant rabbits were given ad libitum access to food (RC4; Oriental Yeast Co., Ltd.) and water during the experiment. [phenyl-14 C] Procymidone was administered to 2 groups of 3 pregnant rabbits each via oral catheter at a dose of 125 mg/kg. The rabbits were then sacrificed: one group 2 hr after administration, and the other group at 24 hr.
Single oral dose in monkeys
Seven female monkeys (4-6 y/o) were purchased on the 50th day of pregnancy (at the initiation of acclimation) from Shin Nippon Biomedical Laboratories (Japan) and used on the 54th day of pregnancy. The health status of the monkeys was checked during an acclimation period of at least 4 days. Pregnant monkeys were limited to approximately 108 g/day of solid food (Teklad Global Certified 25% Protein Primate Diet; Harlan Sprague Dawley Inc., USA) but given ad libitum access to water during the experiment. [phenyl-
14 C] Procymidone was administered to 2 groups of 3 pregnant monkeys each by oral gavage at 125 mg/kg. The monkeys were then sacrificed: one group 6 hr after administration, and the other group at 24 hr.
Repeated oral doses in rats
Pregnant rats were prepared in the same manner as those receiving a single oral dose. Eighteen pregnant rats were separated into 6 groups of 3 rats each. A dose of 125 mg/kg of [phenyl-14 C] procymidone was administered by oral gavage to the first two groups (on GD16), the second two groups on two consecutive days (GD16 and GD17), and to the last two groups on three consecutive days (GD16, GD17, and GD18). The animals were sacrificed 6 and 24 hr after the final dose.
Analysis of the plasma, liver, kidney, amniotic fluid, placenta,
and fetus With each animal under ether anesthesia, blood was collected from the abdominal vein with a heparinized syringe 6 hr (2 hr for the rabbit) and 24 hr after administration and centrifuged to obtain plasma. The time points for blood collection were determined from the results of pharmacokinetic studies for rats, rabbits, and monkeys.
6) The liver, kidney, amniotic fluid, placenta, and fetus were removed and weighed soon after blood collection. To extract metabolites, plasma and other samples were homogenized with acetonitrile and centrifuged to obtain their supernatants. The radioactivity of these supernatants was measured to determine the concentrations of 14 C in samples and to calculate the extraction efficiency. The concentration of 14 C in monkey fetuses was not calculated since the level of radioactivity was too low for significant comparison. TLC analysis was performed for chemical identification and quantification of metabolites in these extracts.
In this study, the transfer ratio was used as the measure of chemical transfer from the maternal plasma to the fetus and calculated from levels of 14 C, 14 C-parent compound, and 14 Chydroxylated compound by using the following formula:
. Pharmacokinetic analysis Plots of total radioactivity, PCM, and Hydroxylated-PCM concentrations in serum vs. the time following animal administration of the parent compound were analyzed using pharmacokinetic analysis software (WAPAS). AUC 0-24 (obtained from 3 time points, rats and monkeys: 0, 6, and 24 hr; rabbits: 0, 2, and 24 hr) was used as an estimate of internal exposure to 14 C, 14 C-PCM, and 14 C-Hydroxylated-PCM and calculated by means of the trapezoidal rule. The C max was determined by using the actual value.
Results
1.
C concentration in pregnant animals
The distribution of 14 C in plasma, tissues, amniotic fluid, and fetuses after a single oral administration of procymidone to pregnant rats, rabbits, and monkeys at 125 mg/kg was determined by radioanalysis (Table 1) . Notably, all plasma and other samples except amniotic fluid showed higher 14 C concentrations 24 hr after administration than at 6 hr in rats, lower 14 C concentrations at 24 hr than at 2 hr in rabbits, and lower 14 C concentrations at 24 hr than at 6 hr in monkeys. Fetuses and amniotic fluid (as compared with maternal plasma and placentas) in all species showed lower 14 C concentrations throughout the experiment. Less than 0.60% and 0.02% of the 14 C dose were, in fact, detectable in the fetuses of rats and rabbits, respectively, 24 hr after administration.
Metabolism in pregnant animals
TLC was used to determine chemical profiles in plasma, tissues, amniotic fluid, and fetuses collected from pregnant rats, rabbits, and monkeys at 6 hr (2 hr for rabbits) and 24 hr after a single oral administration of procymidone. Metabolites were identified by co-chromatography with authentic standards, and then quantified. The concentrations of PCM and its metabolites in plasma and other samples are shown in Table 2 . Rat plasma contained mainly PCM and Hydroxylated-PCM 6 hr after administration, with the concentration of Hydroxylated-PCM having increased by 24 hr. On the other hand, Carboxylated-PCM and Hydroxylated-PCM-glucuronide predominated in rabbit plasma and were present in higher concentration in the kidney than in other samples. The Hydroxylated-PCM concentration was much lower in rabbits than in rats, and the PCM concentration was highest in maternal plasma, and decreased gradually in monkeys. PCM and Hydroxylated-PCM predominated in the fetuses of all species, with concentrations at 24 hr much higher in rat fetuses than in rabbit or monkey fetuses. Notably, the concentration of Hydroxylated-PCM in rat fetuses increased approximately 4.6-fold between 6 and 24 hr after procymidone administration. Hydroxylated-PCM was the main metabolite in rat amniotic fluid and was elevated in concentration 24 hr after the administration of procymidone. The concentration of 14 C in the amniotic fluid of rabbits and monkeys was too low for metabolite level quantitation. 14 C, PCM, and Hydroxylated-PCM, pharmacokinetic parameters (C max and AUC 0-24 ) were calculated from the respective concentrations in the maternal plasma and fetuses of pregnant rats, rabbits, and monkeys after a single oral administration of procymidone (Table 3) . For 14 C, pregnant rats and rabbits had similar maternal plasma C max and AUC 0-24 ; however, rat fetuses had much higher C max and AUC 0-24 , as compared with rabbit and monkey fetuses. For both PCM and Hydroxylated-PCM, rats (as compared with rabbits and monkeys) had much higher maternal plasma and fetus C max and AUC 0-24 .
Metabolism in pregnant rats with repeated oral administration
To clarify changes in the procymidone chemical profile, metabolites in the maternal plasma, fetus, placenta, and amniotic fluid a) Data were calculated from the mean of 3 animals. b) Data were calculated from the mean of 3 animals (2 hr) and 2 animals (24 hr).
were assessed by TLC 6, 24, 30, 48, 54, and 72 hr after the first of several administrations of procymidone at 125 mg/kg/day. Concentrations of metabolites in the plasma, fetus, placenta, and amniotic fluid are shown in Table 4 . Six hr after the first administration, PCM (10.6 µg/g) and Hydroxylated-PCM (4.3 µg/g) were the predominant 14 C-labeled constituents in plasma, and the concentration of Hydroxylated-PCM was observed to reach a maximum 30 hr (14.8 µg/g) after the first administration (6 hr after the second administration), to be decreased at 48 hr (4.0 µg/g), and then returned to the maximum at 54 hr (6 hr after the third administration). Six hours after the first administration, PCM (3.3 µg/g) and Hydroxylated-PCM (2.5 µg/g) were the main 14 C-labeled components in the fetal profile. The concentration of Hydroxylated-PCM in the fetus was 13.0 µg/g 30 hr after administration (6 hr after the second administration), 4.1 µg/g at 48 hr, and 14.6 µg/g (the maximum) at 54 hr (6 hr after the third administration). The concentration and proportion of each metabolite in the placenta and amniotic fluid were almost the same as those in the fetus.
Chemical exposure of the fetus with repeated oral administration
To confirm the transfer of procymidone and metabolites to the fetus after the repeated administration of 125 mg/kg/day procymidone in pregnant rats, the transfer ratios (concentration in fetus/concentration in maternal plasma) of 14 C, 14 C-PCM, and 14 C-Hydroxylated-PCM were calculated from concentrations in maternal plasma and fetuses after repeated oral administration. The transfer ratio of 14 C (Fig. 2) was almost constant (0.41-0.47) until the third administration and thereafter increased (0.53-0.62). The ratio of PCM, as shown in Fig. 3 , remained low 6 hr (0.24-0.36) and 24 hr (0.11-0.18) after each administration. On the other hand, the ratio of Hydroxylated-PCM (Fig. 4) increased gradually until 72 hr after the first administration (0.59-1.69).
To estimate exposure to 14 C, 14 C-PCM, and 14 C-Hydroxylated-PCM in pregnant rats after repeated administration of procymidone, toxicokinetic parameters (C max and AUC 0-24 ) were calculated for the respective concentrations in maternal plasma and fetuses (Table 5) . Repeated dosing had no substantial effect on the C max and AUC 0-24 for PCM in both maternal plasma and fetuses, though they tended to decrease, but did cause the C max and AUC 0-24 for Hydroxylated-PCM to increase in maternal plasma and fetuses.
Discussion
The present study describes the disposition and kinetic parameters for total 14 C, 14 C-PCM, and 14 C-Hydroxylated-PCM in pregnant rats, rabbits, and monkeys after the administration of procymidone. Procymidone was considered to be absorbed rapidly and transformed by oxidation and glucuronidation in all mammalian species. PCM and the products of these transformations including Hydroxylated-PCM, Carboxylated-PCM, and Hydroxylated-PCM-glucuronide, were identified and quantified in the maternal plasma, liver, kidney, placenta, amniotic fluid, and fetus (Fig. 1) . These concentration values were used in direct comparisons among species and calculations of kinetic parameters.
Comparison of toxicokinetics among pregnant animals
The plasma 14 C concentration 24 hr after administration was significantly increased in rats but had rapidly decreased in rabbits to reach the lowest concentration among these three species. The C max of 14 C was higher in rabbits than in rats or monkeys (Table  1) . In pregnant rabbits, a similar kinetic tendency was observed in each sample. Therefore, in pregnant rabbits, as in the intact rabbits, 6 ) absorbed 14 C-procymidone and its metabolites were considered to be rapidly distributed throughout the body via the bloodstream and then rapidly excreted in urine and feces. To estimate the total 14 C exposure, the AUC 0-24 for 14 C in plasma was calculated and compared among rats, rabbits, and monkeys (Table 3 ). The total 14 C exposure was similar in rats and rabbits, but was notably lower in monkeys. The lower total 14 C exposure in monkeys was considered to be due to their lower rate of procymidone absorption. Rats and rabbits showed similar plasma AUC 0-24 of 14 C and rats showed a lower C max of 14 C than did rabbits. These observations were considered to be related to the time of maximum serum concentration (T max ), which was 24 hr and 2 hr after administration in rats and rabbits, respectively. The lower C max in rats was considered to be counterbalanced by the delay in T max . Though the total 14 C exposure was similar between rats and rabbits as described above, there was an obvious species difference between rabbits and rats in the plasma concentration and AUC 0-24 of PCM (Tables 2 and 3) . Further, the kinetic parameters of Hydroxylated-PCM, one of the Fig. 2 . The 14 C concentration in maternal plasma and fetuses, and transfer ratio in pregnant rats after the repeated oral administration (GD16 to 18) of procymidone at 125 mg/kg/day Fig. 3 . The concentration of PCM in maternal plasma and fetuses and the transfer ratio in pregnant rats after the repeated oral administration (GD16 to 18) of procymidone at 125 mg/kg/day Fig. 4 . The concentration of hydroxylated-PCM in maternal plasma and fetuses and the transfer ratio in pregnant rats after the repeated oral administration (GD16 to 18) of procymidone at 125 mg/kg/day major metabolites, were significantly different in the plasma of rats and rabbits or monkeys (Tables 2 and 3 ), and the difference was more obvious for Hydroxylated-PCM than for PCM. Furthermore, the concentration of Hydroxylated-PCM in plasma at 24 hr was much higher than that of PCM in rats. In this analysis of metabolites in rats, Hydroxylated-PCM-glucuronide was not detected in plasma but was detected in the liver. This metabolite can be decomposed biologically to its aglycone Hydroxylated-PCM by hydrolysis in the gastrointestinal tract. Therefore, the increase of Hydroxylated-PCM in plasma until 24 hr after the oral administration of procymidone would be attributable to enterohepatic circulation of the glucuronides, which could extend the biological half-life of Hydroxylated-PCM by reabsorption. The results mentioned above are similar to those in previous studies using intact animals, 6) confirming the hypothesis that Hydroxylated-PCM is a possible key effector of developmental toxcity in rats but not in rabbits or monkeys. Here the hypothesis is reinforced by the results of the placental transfer experiment.
Comparison of tissue distribution among pregnant animals
Procymidone absorption from the gastrointestinal tract was rapid, with maximum 14 C concentrations in maternal plasma and tissues found within 6 hr of administration in rabbits and monkeys, but delayed to 24 hr after administration in rats ( Table  2 ). As described above in rats, the enterohepatic circulation of Hydroxylated-PCM may have contributed to this delay. In rabbits, the 14 C concentration in all analyzed tissues decreased rapidly after reaching the maximum at 2 hr. The main metabolites in rabbit plasma and kidney were Carboxylated-PCM and Hydroxylated-PCM-glucuronide.
In rats, Hydroxylated-PCM was a major metabolite at 24 hr after administration, and its concentration was higher at 24 hr than at 6 hr when the PCM concentration reached a peak in all tissues. This Hydroxylated-PCM profile in rats was not observed in rabbits or monkeys. Therefore, there was concern that the maintenance of a relatively high concentration of Hydroxylated-PCM in the rat fetus might cause adverse effects such as teratogenicity. Consequently, we carried out an additional placental transfer study in pregnant rats to assess the effects of repeated procymidone administration. In the amniotic fluid of rats, the main metabolite, Hydroxylated-PCM, was increased 24 hr after administration. Some of the Hydroxylated-PCM transferred to the fetus was considered to be excreted in the amniotic fluid and to have accumulated gradually. In rabbits, the main metabolites, Carboxylated-PCM and Hydroxylated-PCM-glucuronide, were considered to be excreted rapidly in urine via the kidney.
Placental transfer with repeated oral administration
In the placental transfer study with the repeated administration of procymidone, the concentrations of 14 C, 14 C-PCM, and 14 CHydroxylated-PCM were determined in pregnant rats (Table 4) , and transfer ratios were calculated for each. The placental transfer ratio of 14 C was constant in the range of 0.41-0.62. The placental transfer ratio of PCM was in the range of 0.11-0.36, high at 6 hr after each dosing (0.31, 0.24, and 0.36) and low at 24 hr (0.11, 0.18 and 0.15). On the other hand, the placental transfer ratio of Hydroxylated-PCM gradually increased from 0.59 to 1.69. The fluctuation of the placental transfer ratio for PCM and Hydroxylated-PCM can be attributed to the oxidation of PCM to Hydroxylated-PCM in the fetus. Remember that the first dose was given on gestation day 16 (GD16), when cytochrome P450 becomes functional and can metabolize PCM. [16] [17] [18] In this study, it was therefore demonstrated that (1) PCM and Hydroxylated-PCM are transferred more easily than other metabolites to the fetus in all animals, (2) absolute concentrations of PCM and Hydroxylated-PCM after maternal-fetal transfer are much higher in rat fetuses than in rabbit or monkey fetuses, and (3) notably, the level of Hydroxylated-PCM in the rat fetus is increased with the repeated oral administration of procymidone.
Vinclozolin (a fungicide) and flutamide (a medication), which are known teratogens, have hydroxylated metabolites mainly detected in plasma and act as anti-androgenic agents when activated by metabolism. [19] [20] [21] [22] [23] Procymidone also has hydroxylated metabolites that are mainly detected in plasma and the fetus, although the anti-androgenic activity of these metabolites is much lower than the potent anti-androgenic activity of hydroxylflutamide (the hydroxylated metabolite of flutamide). In a previous report, the anti-androgenic activity of PCM and Hydroxylated-PCM was 20-70 times and 40-140 times lower, respectively, 
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a) Data were calculated from the mean of 3 rats except for 24 hr after the 1st administration (2 rats). b) 6 (30) means 6 hr after the 2nd administration, c) 6 (54) means 6 hr after the 3rd administration.
than that of hydroxyl-flutamide. 12) Although the anti-androgenic activity of Hydroxylated-PCM is very weak, retention of the metabolite by the rat fetus appears to account for its teratogenicity.
These findings suggest that Hydroxylated-PCM is the most relevant metabolite to teratogenic activity in rats.
